180 related articles for article (PubMed ID: 27425383)
1. Reply to Sławomir Poletajew, Piotr Radziszewski, Juan Palou's Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
Arends TJ; Witjes JA
Eur Urol; 2017 Jan; 71(1):e31-e32. PubMed ID: 27425383
[No Abstract] [Full Text] [Related]
2. Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
Arends TJH; Witjes JA
Eur Urol; 2019 Feb; 75(2):e26. PubMed ID: 30268661
[No Abstract] [Full Text] [Related]
3. Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
Poletajew S; Radziszewski P; Palou J
Eur Urol; 2017 Jan; 71(1):e29-e30. PubMed ID: 27417035
[No Abstract] [Full Text] [Related]
4. Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
Garg H; Nayak B; Singh P
Eur Urol; 2019 Feb; 75(2):e25. PubMed ID: 30237025
[No Abstract] [Full Text] [Related]
5. Re: Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer.
Chang SS
J Urol; 2018 Oct; 200(4):696-697. PubMed ID: 30227578
[No Abstract] [Full Text] [Related]
6. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
Lamm D; Böhle A; Palou J; Persad R; Brausi M; Colombel M; Akaza H; Buckley R
Eur Urol; 2010 Feb; 57(2):e7-9; author reply e10-1. PubMed ID: 19914768
[No Abstract] [Full Text] [Related]
7. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
Aldemir M; Canda AE; Balbay MD
Eur Urol; 2010 Aug; 58(2):e23; author reply e24-5. PubMed ID: 20542629
[No Abstract] [Full Text] [Related]
8. Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.
Ooi WL; Stockler M; Hayne D
Eur Urol; 2011 Jul; 60(1):e1; author reply e2-3. PubMed ID: 21489685
[No Abstract] [Full Text] [Related]
9. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
Tan WS; Mustard C; Kelly JD;
Eur Urol; 2023 Feb; 83(2):e48-e49. PubMed ID: 36456403
[No Abstract] [Full Text] [Related]
10. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
Tan WS; Kelly JD;
Eur Urol; 2023 Jan; 83(1):e29-e30. PubMed ID: 36272948
[No Abstract] [Full Text] [Related]
11. Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:60-9.
Sylvester R; Gontero P; Oddens J
Eur Urol; 2016 Jun; 69(6):e123-4. PubMed ID: 26874805
[No Abstract] [Full Text] [Related]
12. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
[TBL] [Abstract][Full Text] [Related]
13. Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62.
Lindgren MS; Jensen JB
Eur Urol; 2021 May; 79(5):e137. PubMed ID: 33593653
[No Abstract] [Full Text] [Related]
14. Chemohyperthermia with Mitomycin-C Compared with Bacillus Calmette-Guérin: A "Hot" Topic.
Oddens JR; Sylvester RJ
Eur Urol; 2016 Jun; 69(6):1053-4. PubMed ID: 26873840
[No Abstract] [Full Text] [Related]
15. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
Sahoo S; Pandey A; Mandal S; Kumar Das M; Nayak P
Eur Urol; 2023 Feb; 83(2):e47. PubMed ID: 36404203
[No Abstract] [Full Text] [Related]
16. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
Campodonico F; Mattioli F; Introini C
Eur Urol; 2023 Feb; 83(2):e56-e57. PubMed ID: 36372625
[No Abstract] [Full Text] [Related]
17. Re: Sequential Intravesical Mitomycin plus Bacillus Calmette-Guérin for Non-Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial.
Chang SS
J Urol; 2016 Sep; 196(3):688-9. PubMed ID: 27597062
[No Abstract] [Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
[TBL] [Abstract][Full Text] [Related]
19. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
[TBL] [Abstract][Full Text] [Related]
20. Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:60-9.
Williams SB; Kamat AM
Eur Urol; 2016 Jun; 69(6):e121-2. PubMed ID: 26874808
[No Abstract] [Full Text] [Related]
[Next] [New Search]